Three Recent Announcements from: Pliant, NGM, and Chemomab
PSC Partners is encouraged by the initial positive data from the CM-101 Phase 2 SPRING Trial which brings hope to our community that an effective treatment may be on the horizon. Of great importance to our community was the news that there were very few side-effects and no safety issues observed in PSC patients treated with CM-101. The decreases in measures of liver injury and fibrosis, as well as the improvement in itch, suggest a potential for improving liver health and symptoms, hopefully slowing the progression of this life-threatening disease.
According to Chemomab Therapeutics, their plan is to discuss the SPRING trial results with the FDA later this year. The goal is to conduct a larger clinical trial that could possibly lead to an approved therapy for people with PSC. Given there are no approved therapies for PSC, it is important to study drugs with unique mechanisms such as CM-101 which targets both inflammation and fibrosis differently than other investigational drugs.
We now have announcements from three companies with investigational PSC drugs that may move forward into larger studies with longer treatment. PSC Partners has been actively engaged with all three companies, supporting these future studies and communicating updates with the PSC patient community. Our team is carefully reviewing the results from these new studies and will continue to share information through our regular channels.
News releases from the sponsors:
Bexotegrast (Pliant Therapeutics)
Aldafermin (NGM Bio)
CM-101 (Chemomab)
Ricky Safer, MA
CEO and Founder, PSC Partners Seeking a Cure
Stephen Rossi, PharmD
CSO, PSC Partners Seeking a Cure
Rachel Gomel, MA
Registry Director, PSC Partners Seeking a Cure
Comments